Patents by Inventor Pierre Schelling

Pierre Schelling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7544684
    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3? and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: June 9, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Pierre Schelling, Thomas Ehring
  • Patent number: 7485639
    Abstract: Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNF?.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: February 3, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Joachim Leibrock, Pierre Schelling, Michael Gassen, Thomas Ehring
  • Patent number: 7470687
    Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: December 30, 2008
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling, Michael Wolf
  • Patent number: 7312224
    Abstract: Pyrimidine derivatives of the formula (I) and physiologically acceptable salts thereof, in which R1, R2, R3, R4, W, X, Y and Z are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of diseases of the cardiovascular system and for the treatment and/or therapy of potency disorders
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: December 25, 2007
    Assignee: Merck Patent GmbH
    Inventors: Hans-Micahel Eggenweiler, Manfred Baumgarth, Pierre Schelling, Norbert Beier, Maria Christadler
  • Patent number: 7259168
    Abstract: The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: August 21, 2007
    Assignee: Merck Patent GmbH
    Inventors: Rochus Jonas, Pierre Schelling, Maria Christadler, Norbert Beier
  • Publication number: 20060270676
    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3? and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: August 2, 2006
    Publication date: November 30, 2006
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Pierre Schelling, Thomas Ehring
  • Patent number: 7141572
    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3? and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: November 28, 2006
    Assignee: Merck Patent Gesellschaft
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Pierre Schelling, Thomas Ehring
  • Patent number: 7135471
    Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: November 14, 2006
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling, Michael Wolf
  • Publication number: 20060205708
    Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: May 8, 2006
    Publication date: September 14, 2006
    Inventors: Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling, Michael Wolf
  • Patent number: 7060823
    Abstract: The present invention relates to 5-aminomethylpyrazolo[4,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: June 13, 2006
    Assignee: Merck Patent GmbH
    Inventors: Rochus Jonas, Pierre Schelling, Maria Christadler, Norbert Beier
  • Patent number: 7019013
    Abstract: The invention relates to compounds of the formula (I) in which R1, E2 and X are as defined above.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: March 28, 2006
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Harry Schwartz, Pierre Schelling, Norbert Beier, Maria Christadler
  • Publication number: 20050209240
    Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: May 16, 2003
    Publication date: September 22, 2005
    Inventors: Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling, Michael Wolf
  • Publication number: 20050070529
    Abstract: The invention relates to the use of type 4 phosphodiesterase inhibitors to treat myocardial diseases.
    Type: Application
    Filed: January 15, 2002
    Publication date: March 31, 2005
    Applicant: Merk Pantent GmbH
    Inventors: Arne Sutter, Thomas Ehring, Thomas Welge, Klause Minck, Claudia Wilm, Michael Gassen, Hans-Michael Eggenweiler, Michael Wolf, Pierre Schelling, Norbert Beier, Joachim Leibrock
  • Publication number: 20040261190
    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: May 4, 2004
    Publication date: December 30, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Pierre Schelling, Thomas Ehring
  • Publication number: 20040242595
    Abstract: Pyrimidine derivatives of formula (I) and 1
    Type: Application
    Filed: April 2, 2004
    Publication date: December 2, 2004
    Inventors: Hans-Michael Eggenweiler, Manfred Baumgarth, Pierre Schelling, Norbert Beier, Maria Christadler
  • Publication number: 20040176252
    Abstract: Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNF&agr;.
    Type: Application
    Filed: January 20, 2004
    Publication date: September 9, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Joachim Leibrock, Pierre Schelling, Michael Gassen, Thomas Ehring
  • Patent number: 6787548
    Abstract: Thienopyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2 and X have the meanings indicated in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: September 7, 2004
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Patent number: 6780867
    Abstract: Thienopyrimidines of the formula (I) and their physiologically acceptable salts, in which R1, R2 and X are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impotence.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: August 24, 2004
    Assignee: Merck Patent GmbH
    Inventors: Rochus Jonas, Hans-Michael Eggenweiler, Pierre Schelling, Maria Christadler, Norbert Beier
  • Patent number: 6777419
    Abstract: Pyrazolo[4,3-d]pyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2, R3, R4 and X have the meanings indicated in Claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: August 17, 2004
    Assignee: Merck Patent GmbH
    Inventors: Rochus Jonas, Hans-Michael Eggenweiler, Pierre Schelling, Maria Christadler, Norbert Beier
  • Publication number: 20040077664
    Abstract: Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor and at least one nitrate for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency and liver cirrhosis.
    Type: Application
    Filed: July 30, 2003
    Publication date: April 22, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann, Pierre Schelling